TOM1L2

Summary

TOM1L2 (target of myb1 like 2 membrane trafficking protein, HGNC:11984) is a protein-coding gene on chromosome 17p11.2, encoding TOM1-like protein 2 (Q6ZVM7). Acts as a MYO6/Myosin VI adapter protein that targets myosin VI to endocytic structures.

This gene belongs to a small gene family whose members have an N-terminal VHS domain followed by a GAT domain; domains which typically participate in vesicular trafficking. The canonical protein encoded by this gene also has a C-terminal clathrin binding motif. This protein has been shown to interact with Tollip, clathrin and ubiquitin and is thought to play a role in endosomal sorting. This gene resides in the 3.7 Mb deletion of chromosome region 17p11.2 that is associated with Smith-Magenis syndrome. Alternative splicing results in multiple transcript variants encoding distinct proteins.

Source: NCBI Gene 146691 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 89 total
• MANE Select transcript: NM_001082968

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11984
Approved symbol	TOM1L2
Name	target of myb1 like 2 membrane trafficking protein
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000175662
Ensembl biotype	protein_coding
OMIM	615519
Entrez	146691

Gene structure

Transcript identifiers

Ensembl transcripts: 39 — 35 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000318094, ENST00000379504, ENST00000395739, ENST00000468944, ENST00000478943, ENST00000486413, ENST00000535933, ENST00000537091, ENST00000540946, ENST00000542206, ENST00000577517, ENST00000577794, ENST00000579586, ENST00000581396, ENST00000890524, ENST00000890525, ENST00000890527, ENST00000890528, ENST00000890532, ENST00000890534, ENST00000890535, ENST00000890537, ENST00000890538, ENST00000890539, ENST00000890541, ENST00000890543, ENST00000890545, ENST00000890546, ENST00000890547, ENST00000890549, ENST00000890550, ENST00000890553, ENST00000890555, ENST00000890557, ENST00000890559, ENST00000890560, ENST00000890561, ENST00000950983, ENST00000950984

RefSeq mRNA: 9 — MANE Select: NM_001082968 NM_001033551, NM_001082968, NM_001288786, NM_001288787, NM_001288788, NM_001288789, NM_001350331, NM_001350332, NM_001350333

CCDS: CCDS32584, CCDS42270, CCDS74000, CCDS74001, CCDS74002, CCDS74003

Canonical transcript exons

ENST00000379504 — 15 exons

Exon	Start	End
ENSE00001481339	17893661	17893810
ENSE00002208769	17972262	17972400
ENSE00002374152	17861476	17861551
ENSE00002389751	17862731	17862848
ENSE00002390291	17850893	17850952
ENSE00003462528	17898596	17898674
ENSE00003477075	17869340	17869473
ENSE00003516626	17866876	17866924
ENSE00003555166	17866296	17866419
ENSE00003558675	17879627	17879743
ENSE00003610108	17882705	17882863
ENSE00003629271	17907447	17907531
ENSE00003635038	17848823	17848859
ENSE00003676655	17884634	17884768
ENSE00004282252	17843511	17847783

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 97.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.8755 / max 159.9668, expressed in 1759 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164809	12.9946	1747
164810	0.8810	513

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	97.88	gold quality
apex of heart	UBERON:0002098	97.86	gold quality
right atrium auricular region	UBERON:0006631	96.79	gold quality
heart left ventricle	UBERON:0002084	96.56	gold quality
right frontal lobe	UBERON:0002810	96.54	gold quality
lower esophagus mucosa	UBERON:0035834	96.46	gold quality
cardiac ventricle	UBERON:0002082	96.40	gold quality
cardiac atrium	UBERON:0002081	96.20	gold quality
tibial nerve	UBERON:0001323	96.14	gold quality
heart	UBERON:0000948	95.56	gold quality
right lobe of thyroid gland	UBERON:0001119	95.55	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.51	gold quality
skin of leg	UBERON:0001511	95.35	gold quality
amygdala	UBERON:0001876	95.28	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.19	gold quality
left lobe of thyroid gland	UBERON:0001120	95.10	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.93	gold quality
nucleus accumbens	UBERON:0001882	94.90	gold quality
thyroid gland	UBERON:0002046	94.75	gold quality
skin of abdomen	UBERON:0001416	94.74	gold quality
cingulate cortex	UBERON:0003027	94.70	gold quality
right coronary artery	UBERON:0001625	94.64	gold quality
substantia nigra pars compacta	UBERON:0001965	94.63	gold quality
anterior cingulate cortex	UBERON:0009835	94.61	gold quality
cerebellar hemisphere	UBERON:0002245	94.51	gold quality
ventral tegmental area	UBERON:0002691	94.50	gold quality
superior vestibular nucleus	UBERON:0007227	94.49	gold quality
trigeminal ganglion	UBERON:0001675	94.46	gold quality
cerebellar cortex	UBERON:0002129	94.44	gold quality
caudate nucleus	UBERON:0001873	94.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.80

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

199 targeting TOM1L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6783-3P	99.89	67.92	2059

Literature-anchored findings (GeneRIF, showing 3)

• Two possible dementia susceptibility genes including ATPAF2 and TOM1L2 near SREBF1 locus were identified. (PMID:20167577)
• Variants in the TOM1L2/SREBF1 locus exert opposing effects of total-body lean mass (TB-LM) and total-body less head bone mineral density (TBLH-BMD) . (PMID:28743860)
• The ancestral ESCRT protein TOM1L2 selects ubiquitinated cargoes for retrieval from cilia. (PMID:37019113)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	tom1l2	ENSDARG00000009217
danio_rerio	TOM1L2	ENSDARG00000056394
mus_musculus	Tom1l2	ENSMUSG00000000538
rattus_norvegicus	Tom1l2	ENSRNOG00000003590
drosophila_melanogaster	Stam	FBGN0027363
drosophila_melanogaster	Gga	FBGN0030141
drosophila_melanogaster	Wdfy2	FBGN0032246
caenorhabditis_elegans	stam-1	WBGENE00004109
caenorhabditis_elegans		WBGENE00008402

Paralogs (10): WDFY1 (ENSG00000085449), GGA1 (ENSG00000100083), TOM1 (ENSG00000100284), GGA2 (ENSG00000103365), STAM2 (ENSG00000115145), GGA3 (ENSG00000125447), STAM (ENSG00000136738), WDFY2 (ENSG00000139668), TOM1L1 (ENSG00000141198), HGS (ENSG00000185359)

Protein

Protein identifiers

TOM1-like protein 2 — Q6ZVM7 (reviewed: Q6ZVM7)

Alternative names: Target of Myb-like protein 2

All UniProt accessions (5): Q6ZVM7, B7Z2U2, F5H3S6, K7EKL6, K7ENB0

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a MYO6/Myosin VI adapter protein that targets myosin VI to endocytic structures. May also play a role in recruiting clathrin to endosomes. May regulate growth factor-induced mitogenic signaling.

Subunit / interactions. Interacts with clathrin, SRC and TOLLIP. Interacts with MYO6.

Tissue specificity. Ubiquitously expressed with higher expression in heart and skeletal muscle.

Domain organisation. The GAT domain mediates interaction with TOLLIP.

Similarity. Belongs to the TOM1 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q6ZVM7-1	1	yes
Q6ZVM7-2	2
Q6ZVM7-3	3
Q6ZVM7-4	4
Q6ZVM7-5	5

RefSeq proteins (9): NP_001028723, NP_001076437, NP_001275715, NP_001275716, NP_001275717, NP_001275718, NP_001337260, NP_001337261, NP_001337262 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002014	VHS_dom	Domain
IPR004152	GAT_dom	Domain
IPR008942	ENTH_VHS	Homologous_superfamily
IPR014645	TOM1	Family
IPR027429	TOM1L2_VHS_dom	Domain
IPR038425	GAT_sf	Homologous_superfamily

Pfam: PF00790, PF03127

UniProt features (22 total): sequence conflict 8, splice variant 5, domain 2, region of interest 2, modified residue 2, chain 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZVM7-F1	71.13	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 160, 164

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 208 (showing top): GOBP_REGULATION_OF_NUCLEAR_DIVISION, XU_GH1_AUTOCRINE_TARGETS_UP, GOZGIT_ESR1_TARGETS_DN, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, RICKMAN_METASTASIS_DN, GOBP_ORGANELLE_FISSION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, USF_01, GOBP_MITOTIC_NUCLEAR_DIVISION, HNF4_DR1_Q3, HFH4_01, GOBP_NEGATIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, PPAR_DR1_Q2

GO Biological Process (3): signal transduction (GO:0007165), protein transport (GO:0015031), negative regulation of mitotic nuclear division (GO:0045839)

GO Molecular Function (5): protein kinase binding (GO:0019901), clathrin binding (GO:0030276), phosphatidylinositol binding (GO:0035091), ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (3): endosome (GO:0005768), membrane (GO:0016020), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
regulation of mitotic nuclear division	1
negative regulation of cell cycle process	1
negative regulation of mitotic cell cycle	1
negative regulation of nuclear division	1
mitotic nuclear division	1
kinase binding	1
protein binding	1
anion binding	1
ubiquitin-like protein binding	1
binding	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

1004 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TOM1L2	ZFYVE16	Q7Z3T8	886
TOM1L2	EEA1	Q15075	700
TOM1L2	APPL1	Q9UKG1	615
TOM1L2	LMTK2	Q8IWU2	534
TOM1L2	DAB2	P98082	528
TOM1L2	TOLLIP	Q9H0E2	500
TOM1L2	ICA1L	Q8NDH6	467
TOM1L2	RTF2	Q9BY42	461
TOM1L2	SRC	P12931	433
TOM1L2	MYO6	Q9UM54	426
TOM1L2	GIPC1	O14908	387
TOM1L2	SNX32	Q86XE0	376
TOM1L2	SLCO6A1	Q86UG4	372
TOM1L2	ATPAF2	Q8N5M1	372
TOM1L2	DRG2	P55039	355

IntAct

55 interactions, top by confidence:

A	B	Type	Score
TOLLIP	TOM1	psi-mi:“MI:0914”(association)	0.890
ARRDC3	WWP2	psi-mi:“MI:0914”(association)	0.770
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
MYO6	GIPC1	psi-mi:“MI:0914”(association)	0.690
MYO6	TOM1L2	psi-mi:“MI:0915”(physical association)	0.610
MYO6	TOM1	psi-mi:“MI:0914”(association)	0.530
TOM1L2	NDUFA6	psi-mi:“MI:0914”(association)	0.530
CUEDC1	TOM1	psi-mi:“MI:0914”(association)	0.530
CTLA4	B4GALT5	psi-mi:“MI:0914”(association)	0.530
TMEM171	B3GAT3	psi-mi:“MI:0914”(association)	0.530
TRIM10	WIZ	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
TOM1L2	RNF11	psi-mi:“MI:0915”(physical association)	0.370
LAPTM5	TOM1L2	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
rep	ABLIM1	psi-mi:“MI:0914”(association)	0.350
CTBP1	TAF15	psi-mi:“MI:0914”(association)	0.350
ESR1	ARPC1B	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
CALM1	MYO1C	psi-mi:“MI:0914”(association)	0.350
CALM2	MYO1C	psi-mi:“MI:0914”(association)	0.350

BioGRID (95): TOM1L2 (Biochemical Activity), AGL (Co-fractionation), TOM1L2 (Affinity Capture-MS), TOM1L2 (Biochemical Activity), CUEDC1 (Affinity Capture-MS), SZRD1 (Affinity Capture-MS), NDUFA6 (Affinity Capture-MS), TOM1L2 (Reconstituted Complex), TOM1L2 (Two-hybrid), TOM1L2 (Proximity Label-MS), TOM1L2 (Proximity Label-MS), TOM1L2 (Affinity Capture-MS), TOM1L2 (Affinity Capture-MS), TOM1L2 (Two-hybrid), FAM9B (Two-hybrid)

ESM2 similar proteins: A0A8C0TYJ0, A0A8I5ZNK2, A2AWA9, A6QQZ7, A8KBF6, O55047, O88506, O95747, P20936, P23727, P26450, P27986, P31016, P78352, Q08CW1, Q08E27, Q12959, Q15139, Q15700, Q1ECX4, Q28C55, Q5PYH5, Q5PYH6, Q5PYH7, Q5R372, Q5R495, Q5R685, Q5R6Y5, Q5RAN1, Q5RCW6, Q5SRX1, Q5T2T1, Q5U2Y3, Q5ZIL4, Q5ZMW5, Q62101, Q62108, Q62696, Q63622, Q68FK8

Diamond homologs: A0A0D1E015, A0JMD2, A1CEK1, A1DFN5, A1DFP5, A2QWA2, A3LX75, A4QTV1, A8QCE4, A8XJZ8, B0WAQ0, B3MT31, B3P851, B4G2G5, B4IC49, B4JHI7, B4K982, B4M140, B4NFJ7, B4PRU6, E9Q4P1, F4KAU9, O12940, O13821, O14964, O60784, O76902, O88746, P0CR78, P0CR79, P0CS26, P0CS27, P38817, P40343, P87157, Q0CJU8, Q0CJV3, Q0P4S0, Q0U4Z8, Q0U6X7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SMURF1	unknown	TOM1L2	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3412 predictions. Top by Δscore:

Variant	Effect	Δscore
17:17847780:AACT:A	acceptor_gain	1.0000
17:17847781:ACTC:A	acceptor_loss	1.0000
17:17847782:CT:C	acceptor_gain	1.0000
17:17847783:TCTGC:T	acceptor_loss	1.0000
17:17847784:C:CC	acceptor_gain	1.0000
17:17847784:CTGCA:C	acceptor_loss	1.0000
17:17847785:T:G	acceptor_loss	1.0000
17:17848648:T:TA	donor_gain	1.0000
17:17848855:CCCTT:C	acceptor_gain	1.0000
17:17848856:CCTTC:C	acceptor_gain	1.0000
17:17862729:A:AC	donor_gain	1.0000
17:17862730:C:CC	donor_gain	1.0000
17:17862730:CGT:C	donor_gain	1.0000
17:17862732:T:TA	donor_gain	1.0000
17:17866874:A:AC	donor_gain	1.0000
17:17866874:ACT:A	donor_gain	1.0000
17:17866875:C:CC	donor_gain	1.0000
17:17866875:CT:C	donor_gain	1.0000
17:17866875:CTC:C	donor_gain	1.0000
17:17869336:CCACC:C	donor_loss	1.0000
17:17869337:CA:C	donor_loss	1.0000
17:17869339:C:A	donor_loss	1.0000
17:17869339:CCT:C	donor_gain	1.0000
17:17879622:CTCA:C	donor_loss	1.0000
17:17879623:TCA:T	donor_loss	1.0000
17:17879624:CA:C	donor_loss	1.0000
17:17879744:C:CC	acceptor_gain	1.0000
17:17879755:C:CT	acceptor_gain	1.0000
17:17879755:C:T	acceptor_gain	1.0000
17:17879757:C:CT	acceptor_gain	1.0000

AlphaMissense

3309 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:17869367:A:G	L295P	1.000
17:17869469:A:G	L261P	1.000
17:17884765:A:G	W124R	1.000
17:17884765:A:T	W124R	1.000
17:17847768:A:G	L464P	0.999
17:17847768:A:T	L464H	0.999
17:17847770:G:C	F463L	0.999
17:17847770:G:T	F463L	0.999
17:17847771:A:G	F463S	0.999
17:17847772:A:G	F463L	0.999
17:17847779:A:C	F460L	0.999
17:17847779:A:T	F460L	0.999
17:17847781:A:G	F460L	0.999
17:17869385:A:G	L289P	0.999
17:17869388:A:G	L288P	0.999
17:17869427:A:G	L275P	0.999
17:17879631:A:G	L258P	0.999
17:17879712:A:T	V231D	0.999
17:17884650:A:T	I162K	0.999
17:17884682:A:C	F151L	0.999
17:17884682:A:T	F151L	0.999
17:17884683:A:G	F151S	0.999
17:17884684:A:G	F151L	0.999
17:17884704:A:G	L144P	0.999
17:17893668:A:G	L120P	0.999
17:17893674:A:G	L118P	0.999
17:17893784:A:C	C81W	0.999
17:17893787:G:C	N80K	0.999
17:17893787:G:T	N80K	0.999
17:17893790:C:A	K79N	0.999

dbSNP variants (sampled 300 via entrez): RS1000016495 (17:17853739 G>A), RS1000030337 (17:17899858 A>C,T), RS1000031462 (17:17860009 C>A), RS1000038483 (17:17898531 G>A,C,T), RS1000056977 (17:17871434 C>T), RS1000065230 (17:17858528 G>A), RS1000095405 (17:17949598 G>A), RS1000096832 (17:17863807 C>T), RS1000099564 (17:17929065 G>A), RS1000147623 (17:17949906 T>C), RS1000164601 (17:17879803 A>G), RS1000181724 (17:17961137 C>T), RS1000182520 (17:17967778 T>A), RS1000194638 (17:17875899 T>C), RS1000222278 (17:17892267 C>T)

Disease associations

OMIM: gene MIM:615519 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002539_86	Schizophrenia	2.000000e-08
GCST004771_10	TB-LM or TBLH-BMD (pleiotropy)	1.000000e-10
GCST004946_149	Schizophrenia	7.000000e-10
GCST005348_40	Total body bone mineral density	2.000000e-11
GCST006803_40	Schizophrenia	3.000000e-08
GCST90020025_1401	Waist-to-hip ratio adjusted for BMI	1.000000e-09
GCST90020026_432	Hip index	1.000000e-09
GCST90020027_28	Waist-hip index	2.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004995	lean body mass
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	5
Valproic Acid	decreases expression, increases expression, increases methylation	3
sodium arsenite	decreases expression, increases abundance, increases expression, affects cotreatment	2
Acetaminophen	decreases expression, increases expression	2
Arsenic	decreases expression, increases abundance, affects cotreatment	2
Tretinoin	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
polyhexamethyleneguanidine	affects expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol B	increases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
bisphenol S	decreases methylation	1
(+)-JQ1 compound	increases expression	1
Vehicle Emissions	decreases reaction, increases expression	1
Caffeine	decreases phosphorylation	1
Dexamethasone	increases expression	1
Furaldehyde	affects cotreatment, affects localization, decreases expression	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1
Manganese	decreases expression, increases abundance	1
Potassium Dichromate	decreases expression	1
Sodium Chloride	affects cotreatment, affects localization, decreases expression	1
Tobacco Smoke Pollution	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.